Positive Market Insights for Haleon Plc Amid EPS Estimate Adjustments
Haleon Plc Stock Analysis
Recent assessments by Morgan Stanley reveal a cautiously optimistic outlook for Haleon Plc (NYSE:HLN). The investment firm has slightly reduced its price target for the company's shares from $10.95 to $10.65. This revision, however, has not affected their Overweight rating on the stock, indicating confidence in Haleon’s future performance. The changes come as analysts prepare for the anticipated quarterly results set to unveil later in the year.
Growth Forecasts and Expectations
Despite the modest adjustment, Morgan Stanley has held steady on its year-over-year organic growth estimate for fiscal year 2024 at 5.0%, which is slightly ahead of the consensus projection of 4.9%. Nonetheless, the firm has recalibrated its expectations for third-quarter growth, now estimating growth at 6.3%, down from a previous forecast of 7.5%. This downward adjustment reflects a projected tougher environment for the vitamin, mineral, and supplement (VMS) segment in the U.S., prompted by current market dynamics and past performance benchmarks.
Impact of Market Changes
In addition to the growth adjustments, the anticipated margins for Haleon have been slightly lowered from 22.9% to 22.6%. This revision considers the consequences of the recent divestment of the Nicotine Replacement Therapy (NRT) business and shifts in foreign exchange rates. Despite these changes, Morgan Stanley still envisions a robust 9% organic EBIT growth trajectory for the full fiscal year.
EPS Forecast Adjustments
The firm has also lowered the earnings per share (EPS) estimates for fiscal years 2025 and 2026 by less than 1%. This slight decline comes after reviewing the implications of Haleon increasing its stake in its joint venture based in China, prompting adjustments in the price target alongside updates in the USD/GBP exchange rates.
Corporate Developments at Haleon
Recently, Haleon has been active in the capital markets, notably completing a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE). Furthermore, the consumer healthcare leader finalized the sale of its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for a deal potentially reaching £500 million. Additionally, Haleon has increased its stake in the Tianjin TSKF Pharmaceutical Co. Ltd joint venture to an impressive 88%.
Analyst Perspectives
Several analysts have recently modified their outlook on Haleon. Morgan Stanley and BofA Securities have uplifted their price targets, while Goldman Sachs has shifted its rating from "Buy" to "Neutral." Meanwhile, Berenberg has begun covering the stock, issuing a favorable "Buy" rating in their analysis. The company also made headlines with the launch of Eroxon®, the inaugural FDA-cleared over-the-counter gel in the U.S. for treating erectile dysfunction.
Board Changes and Governance
In terms of corporate governance, recent board changes included the resignation of Alan Stewart. The company has also smoothly executed a share buyback program to bolster its employee share schemes for the year 2025.
Key Financial Insights
Exploring further insights, current data highlights Haleon’s market capitalization at around $44.76 billion, illustrating its strong foothold in the healthcare sector. The company showcases robust gross profit margins, currently reported at 62.54% for the last twelve months as of Q2 2024, complementing Morgan Stanley's encouraging outlook on organic EBIT growth.
Competitiveness and Market Position
InvestingPro insights reveal Haleon is operating at a moderate debt level, signifying a healthy financial structure that supports profitability in the face of market challenges. However, its revenue growth trajectory remains somewhat flat, with a recent slight decrease of 1.31%. This stagnation can be attributed to difficulties within the VMS segment. Conversely, a minor quarterly revenue growth of 0.84% in Q2 2024 suggests a possible reversal in fortunes ahead.
Frequently Asked Questions
What is Haleon Plc’s current stock price target?
Morgan Stanley recently adjusted Haleon's price target to $10.65.
What growth is expected for Haleon in fiscal year 2024?
Haleon is projected to achieve a 5.0% organic growth in fiscal year 2024.
What recent corporate actions has Haleon taken?
Haleon completed a significant share repurchase and divested its nicotine replacement therapy business.
How does Haleon's market capitalization reflect its position?
Haleon has a market capitalization of approximately $44.76 billion, indicating its strength in consumer healthcare.
Which notable product did Haleon launch recently?
Haleon launched Eroxon®, the first FDA-cleared over-the-counter gel for erectile dysfunction in the U.S.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Bellring Brands Achieves Record Stock High Amid Market Optimism
- Upcoming Earnings Call of California Water Service Group
- The RealReal Gear Up for November Earnings Review Call
- MediaAlpha Set for Q3 2024 Financial Results Presentation
- Informatica Welcomes Mitesh Dhruv to Board Enhancing Leadership
- Denali Therapeutics' Strategic Shift Amid Multiple Sclerosis Study
- SELLAS Life Sciences to Share Insights at Upcoming Virtual Summit
- Itron's Upcoming Q3 Earnings Call: Key Insights and Expectations
- Vishay Precision Group Sets Conference Call for Q3 Earnings
- QIAGEN Enhances Liquid Biopsy Solutions for Medical Advancements
Recent Articles
- ADMA Biologics Sees Stock Fluctuations Amidst Auditor Transition
- Analysts Praise Atlas Energy Solutions Amidst Challenges
- GXO Logistics: Strong Buy Rating Amid Sale Speculation
- BRICS Nations Challenge IMF Dominance with New Financial Solutions
- Emergence of Drug-Resistant Mpox Strain Raises Concerns
- Exciting PlayStation Plus October Update Features 14 Games
- Understanding Recent Movements in First Solar Stock Value
- Join the WEBTOON Class Action: Important Deadlines Ahead
- Current Trends Impacting Faraday Future's Stock Performance
- ClimateTech Connect: Pioneering a Green Future in Washington
- Experience the Epic Conclusion of Dune: Part Two on Screen
- Shell plc's Recent Share Purchases: Key Insights Revealed
- Origin Bancorp Prepares for Q3 Earnings Conference Call
- Levi & Korsinsky Files Complaint for UPS Investors to Seek Recovery
- Vast's Revolutionary Haven-1 Design Sets New Space Standards
- Marriott Strengthens Security Following $52M Settlement from Breaches
- AKF Launches Urgent Relief Program for Kidney Patients Post-Hurricane
- Unlocking Savings: Save A Lot Introduces Loyalty Rewards
- Origin Bancorp Reveals Upcoming Earnings Call Details
- Discover How $1,000 in Honeywell Could Grow to $6,500
- Mount Sinai Enhances Patient Care with Advanced Far-UVC Tech
- Transforming $1000 Into $190,000: The Celsius Journey
- Leipurin Successfully Completes Exit from Russian Operations
- Celsius Holdings Sees Stock Surge Amid Retail Trader Interest
- Orange Confirms Successful Consent Solicitation for 2031 Notes
- Cyrq Energy Welcomes Mark Sudbey as New CEO Driving Growth
- Unpacking GE Vernova's Options Trading Insights
- Nutrien Set to Announce Third Quarter 2024 Financial Results
- Inszone Insurance Services Expands Operations Through Acquisition
- Understanding Recent Trends in Philip Morris Intl's Options Market
- Innovative Home Financing: The Partnership of Financial Dwellings and Calque
- CEG Options Activity Indicates Insights from Smart Investors
- Investigation into Forza X1 Acquisition Proposal: Key Insights
- Top Tips to Combat Cold and Flu Symptoms Effectively
- Whales Signal Caution with Albemarle's Stock Bets
- Investigation into the Merger of Primo Water Corporation
- Westat Awarded MEPS-HC by AHRQ to Enhance Healthcare Research
- Insightful Trends in Schlumberger's Recent Stock Movements
- Explore the Features and Pricing of the 2025 Subaru Crosstrek
- AECOM Strengthens Position with Southern Water's Major Initiative
- Jeep and Mopar Celebrate Indigenous Students with Scholarships
- Innovative Bladder Device Study Receives FDA Approval
- BTIG Forecasts Bright Future for Birkenstock's Growth
- PG&E Awards $900,000 in Grants for Climate Resilience Efforts
- Italy Considers Westinghouse and EDF for Nuclear Power Project
- Community Gaming Forms Strategic Alliance with Moonton for MLBB
- B.Riley's Neutral Outlook on Yeti Holdings and Market Trends
- Laguna: The Revolutionary App Transforming Online Dating
- Ballard Power Systems Faces New Challenges with Stock Decline
- Alchemy Pay Expands Virtual Card Capabilities with Samsung Pay